S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EIGR

Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis

$5.00
+0.02 (+0.40%)
(As of 03/28/2024 ET)
Today's Range
$5.00
$5.14
50-Day Range
$4.81
$7.17
52-Week Range
$4.79
$43.35
Volume
3,982 shs
Average Volume
11,266 shs
Market Capitalization
$7.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$120.00

Eiger BioPharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,300.0% Upside
$120.00 Price Target
Short Interest
Healthy
2.56% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.52mentions of Eiger BioPharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($49.25) to ($15.62) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.72 out of 5 stars

EIGR stock logo

About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

EIGR Stock Price History

EIGR Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
EIGR Eiger BioPharmaceuticals, Inc.
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Why Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?
Eiger to discontinue hepatitis drug study
Citi Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)
See More Headlines
Receive EIGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:EIGR
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$120.00
High Stock Price Target
$150.00
Low Stock Price Target
$90.00
Potential Upside/Downside
+2,295.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-96,780,000.00
Net Margins
-590.80%
Pretax Margin
-590.79%

Debt

Sales & Book Value

Annual Sales
$13.48 million
Book Value
$37.68 per share

Miscellaneous

Free Float
1,416,000
Market Cap
$7.41 million
Optionable
Optionable
Beta
1.85
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. David Apelian M.B.A. (Age 59)
    M.D., Ph.D., CEO & Director
    Comp: $204.39k
  • Dr. Jeffrey S. Glenn M.D. (Age 61)
    Ph.D., Scientific Founder & Independent Director
    Comp: $67k
  • Mr. William G. Kaichoff CPA (Age 58)
    CFO and Principal Financial & Accounting Officer
  • Mr. Christopher A. Kurtz (Age 57)
    Chief Technical Officer
  • Mr. James Vollins J.D. (Age 55)
    General Counsel, Chief Compliance Officer & Corporate Secretary
  • Dr. Colin Hislop M.D. (Age 66)
    MBBS, Senior Vice President of Clinical & Development Operations
  • Dr. Colleen Craig M.D.
    Senior Vice President of Metabolic Diseases

EIGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Eiger BioPharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EIGR shares.
View EIGR analyst ratings
or view top-rated stocks.

What is Eiger BioPharmaceuticals' stock price target for 2024?

2 brokers have issued 12-month price objectives for Eiger BioPharmaceuticals' stock. Their EIGR share price targets range from $90.00 to $150.00. On average, they anticipate the company's stock price to reach $120.00 in the next year. This suggests a possible upside of 2,300.0% from the stock's current price.
View analysts price targets for EIGR
or view top-rated stocks among Wall Street analysts.

How have EIGR shares performed in 2024?

Eiger BioPharmaceuticals' stock was trading at $6.7350 at the start of the year. Since then, EIGR stock has decreased by 25.8% and is now trading at $5.00.
View the best growth stocks for 2024 here
.

Are investors shorting Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals saw a decrease in short interest in March. As of March 15th, there was short interest totaling 33,600 shares, a decrease of 18.8% from the February 29th total of 41,400 shares. Based on an average daily trading volume, of 11,800 shares, the short-interest ratio is currently 2.8 days. Approximately 2.6% of the shares of the company are short sold.
View Eiger BioPharmaceuticals' Short Interest
.

When is Eiger BioPharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our EIGR earnings forecast
.

How were Eiger BioPharmaceuticals' earnings last quarter?

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share for the quarter, missing the consensus estimate of ($17.40) by $2.10. The biotechnology company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. During the same quarter in the prior year, the firm earned ($15.60) earnings per share.

What ETF holds Eiger BioPharmaceuticals' stock?

Simplify Propel Opportunities ETF holds 1,099,653 shares of EIGR stock, representing 0.75% of its portfolio.

When did Eiger BioPharmaceuticals' stock split?

Eiger BioPharmaceuticals shares reverse split before market open on Monday, January 8th 2024. The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Eiger BioPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO).

Who are Eiger BioPharmaceuticals' major shareholders?

Eiger BioPharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (123.02%), Vanguard Group Inc. (123.02%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Richard A Kayne, Sriram Ryali and Thomas John Dietz.
View institutional ownership trends
.

How do I buy shares of Eiger BioPharmaceuticals?

Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EIGR) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners